Evidence map›Paper›PMID 36003074›Full record

ArticlePNAS nexus2022

Charge-based interactions through peptide position 4 drive diversity of antigen presentation by human leukocyte antigen class I molecules.

Kyle R Jackson, Dinler A Antunes, Amjad H Talukder, Ariana R Maleki, Kano Amagai, Avery Salmon, Arjun S Katailiha, Yulun Chiu, Romanos Fasoulis, Maurício Menegatti Rigo and 18 more

Abstract read
In one paragraph

Article in PNAS nexus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Kyle R JacksonUniversity of Texas MD Anderson Cancer Center, UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
Dinler A AntunesDepartment of Biology and Biochemistry, University of Houston, Houston, TX, USA.
Amjad H TalukderDepartment of Melanoma, UT MD Anderson Cancer Center, Houston, TX, USA.
Ariana R MalekiDepartment of Melanoma, UT MD Anderson Cancer Center, Houston, TX, USA.
Kano AmagaiDepartment of Melanoma, UT MD Anderson Cancer Center, Houston, TX, USA.
Avery SalmonUniversity of Texas MD Anderson Cancer Center, UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
Arjun S KatailihaDepartment of Melanoma, UT MD Anderson Cancer Center, Houston, TX, USA.
Yulun ChiuDepartment of Melanoma, UT MD Anderson Cancer Center, Houston, TX, USA.
Romanos FasoulisDepartment of Computer Science, Rice University, Houston, TX, USA.
Maurício Menegatti RigoDepartment of Computer Science, Rice University, Houston, TX, USA.
Jayvee R AbellaDepartment of Computer Science, Rice University, Houston, TX, USA.ORCID https://orcid.org/0000-0002-8574-1144
Brenda D MelendezUniversity of Texas MD Anderson Cancer Center, UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
Fenge LiDepartment of Melanoma, UT MD Anderson Cancer Center, Houston, TX, USA.
Yimo SunUniversity of Texas MD Anderson Cancer Center, UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
Heather M SonnemannUniversity of Texas MD Anderson Cancer Center, UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
Vladislav BelousovBostonGene Corporation, Waltham, MA, USA.
Felix FrenkelBostonGene Corporation, Waltham, MA, USA.
Sune JustesenImmunitrack Aps, Copenhagen, Denmark.
Aman MakajuThermoFisher Scientific, San Jose, CA, USA.
Yang LiuThermoFisher Scientific, San Jose, CA, USA.
David HornThermoFisher Scientific, San Jose, CA, USA.
Daniel Lopez-FerrerThermoFisher Scientific, San Jose, CA, USA.
Andreas F HuhmerThermoFisher Scientific, San Jose, CA, USA.
Patrick HwuDepartment of Melanoma, UT MD Anderson Cancer Center, Houston, TX, USA.
Jason RoszikDepartment of Melanoma, UT MD Anderson Cancer Center, Houston, TX, USA.ORCID https://orcid.org/0000-0002-4561-6170
David HawkeDepartment of Systems Biology, UT MD Anderson Cancer Center, Houston, TX, USA.ORCID https://orcid.org/0000-0002-6102-7843
Lydia E KavrakiDepartment of Computer Science, Rice University, Houston, TX, USA.
Gregory LizéeDepartment of Melanoma, UT MD Anderson Cancer Center, Houston, TX, USA.ORCID https://orcid.org/0000-0003-4449-7461

Funding

PROTEAN-CR: Proteomics Toolkit for Ensemble Analysis in Cancer ResearchU01CA258512 · NCI · RICE UNIVERSITY · PI KAVRAKI, LYDIA E., LIZEE, GREGORY A · 2021 to 2023
$1.2M
Structure-based selection of tumor-antigens for T-cell based immunotherapyR21CA209941 · NCI · RICE UNIVERSITY · PI KAVRAKI, LYDIA E., LIZEE, GREGORY A · 2016 to 2017
$384k
NCI NIH HHS R21 CA209941NCI NIH HHS U01 CA258512
6 · The paper itself

Abstract

Human leukocyte antigen class I (HLA-I) molecules bind and present peptides at the cell surface to facilitate the induction of appropriate CD8+ T cell-mediated immune responses to pathogen- and self-derived proteins. The HLA-I peptide-binding cleft contains dominant anchor sites in the B and F pockets that interact primarily with amino acids at peptide position 2 and the C-terminus, respectively. Nonpocket peptide-HLA interactions also contribute to peptide binding and stability, but these secondary interactions are thought to be unique to individual HLA allotypes or to specific peptide antigens. Here, we show that two positively charged residues located near the top of peptide-binding cleft facilitate interactions with negatively charged residues at position 4 of presented peptides, which occur at elevated frequencies across most HLA-I allotypes. Loss of these interactions was shown to impair HLA-I/peptide binding and complex stability, as demonstrated by both in vitro and in silico experiments. Furthermore, mutation of these Arginine-65 (R65) and/or Lysine-66 (K66) residues in HLA-A*02:01 and A*24:02 significantly reduced HLA-I cell surface expression while also reducing the diversity of the presented peptide repertoire by up to 5-fold. The impact of the R65 mutation demonstrates that nonpocket HLA-I/peptide interactions can constitute anchor motifs that exert an unexpectedly broad influence on HLA-I-mediated antigen presentation. These findings provide fundamental insights into peptide antigen binding that could broadly inform epitope discovery in the context of viral vaccine development and cancer immunotherapy.

Indexed as

computational modelinghuman leukocyte antigen (HLA)mass spectrometrymolecular dynamicspeptide antigen presentation

Identifiers

PMID36003074
PMCPMC9391200

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.